MK-777
Acetamoren — MK-677 analog GHS
MK-777 (Acetamoren — MK-677 analog GHS) is a gh & growth research compound. Described as a non-peptide agonist at the ghrelin receptor (GHS-R1a) — the same receptor MK-677 acts on, and the same one the injectable ghrelin mimetics (Ipamorelin, GHRP-2/6) hit. Binding there triggers a GH pulse, which raises IGF-1 downstream. Orally bioavailable, which is the practical difference from the peptide secretagogues. Read that mechanism as a CLASS ASSIGNMENT rather than a measured finding: it follows from what the compound is sold as, and no published pharmacology confirms it.
MK-777 quick facts
| Route | Oral |
| Frequency | 1x Daily |
| Half-life | Unknown — MK-677's is ~24 hrs, but that is the predecessor, not this |
| Forms | Oral |
| Evidence level | None independent — no PubMed entry, no trial registry record, no published pharmacology. Every description traces to vendor copy. |
The newest thing in this section and the least supported. It is sold as a next-generation MK-677, and the entire case for it is that positioning — there is no trial, no paper, and no regulator has looked at it. IF IT WORKS THE WAY IT IS SOLD, IT IS A GHRELIN MIMETIC, WHICH MEANS RUNNING IT ALONGSIDE MK-677, IPAMORELIN OR A GHRP IS NOT A STACK — IT IS A DOUBLE DOSE OF THE SAME RECEPTOR. That is the practical risk here, and it is the one people will walk into. The '92% greater binding affinity than MK-677' figure repeated across vendor sites has no source anyone can follow. Treat it as marketing. The dose shown is DA's capsule size read across from MK-677's usual range; nobody has established a dose for this molecule.
How MK-777 works
Described as a non-peptide agonist at the ghrelin receptor (GHS-R1a) — the same receptor MK-677 acts on, and the same one the injectable ghrelin mimetics (Ipamorelin, GHRP-2/6) hit. Binding there triggers a GH pulse, which raises IGF-1 downstream. Orally bioavailable, which is the practical difference from the peptide secretagogues. Read that mechanism as a CLASS ASSIGNMENT rather than a measured finding: it follows from what the compound is sold as, and no published pharmacology confirms it.
Proposed benefits
Researched for lean-mass support, recovery, sleep depth, connective-tissue repair and improved body composition via the GH/IGF-1 axis.
Where to get MK-777
Buy MK-777 at Disguised Alpha →The evidence for MK-777
Graded by what exists behind each claim.
✅ Clinically validated
- None. No PubMed entry, no clinical trial registry record, no published pharmacology. This is not a compound with thin human data — it is a compound with no independent data of any kind. Every description of it traces back to a vendor or a supplement retailer.
- The '92% greater binding affinity than MK-677' figure has no source. It appears on several sales pages with no citation attached anywhere. It is named here so a reader who meets it knows it is untraceable, rather than assuming nobody checked.
📊 Correlative data
- MK-677 is the only real read available, and it is the honest comparator because MK-777 is sold explicitly as its successor. MK-677 reliably raises IGF-1, reliably raises appetite, and reliably causes fluid retention and a drift toward insulin resistance.
- MK-677 also failed the outcome that mattered most: its hip-fracture trial in older adults did not deliver. Raising IGF-1 is not the same as producing a clinical result, and that is the most useful lesson the predecessor offers a compound with none of its own.
🧪 Theoretical / extrapolated
- Sold as a non-peptide agonist at the ghrelin receptor, GHS-R1a — the same receptor MK-677 and the injectable ghrelin mimetics act on. Oral bioavailability is the claimed practical advantage over the peptides.
- The consequence people miss: this is a ghrelin mimetic. Running it beside MK-677, Ipamorelin, GHRP-2 or GHRP-6 is not a stack of two things — it is a double dose at one receptor. A GHRH analog (CJC-1295, Sermorelin) is the arm that genuinely pairs with it.
- Treat the mechanism as a class assignment inherited from what it is sold as, not as a measured property of this molecule.
How to read these tiers: they say how much human evidence exists, not how well something works — and ✗ flags harm, never a disappointing trial. How the evidence tiers work →
What MK-777 actually does
The honest first sentence about MK-777 is that nobody outside the companies selling it knows what it is. A search of NCBI's PubTator3 index for MK-777 and for acetamoren returns zero records. Not thin literature — none. No structure in PubChem under either name, no clinical trial registry entry, no pharmacology paper, no patent anybody has cited. Everything on every page describing this compound, including the mechanism sentence on this one, is a class assignment inherited from its marketing.
So this section describes the receptor it is claimed to act at, and labels that clearly as what it is. If MK-777 is what it is sold as, it is a non-peptide agonist at GHS-R1a, the growth hormone secretagogue receptor. That receptor is now understood at atomic resolution: Liu 2021 solved cryo-electron microscopy structures of the human ghrelin receptor bound to ghrelin and to the synthetic agonist ibutamoren — MK-677 — and described how each engages the binding pocket and how the receptor activates.
What that structural work tells you, and it is directly relevant to a compound claiming to be an improved MK-677. Ibutamoren is a spiropiperidine, not a peptide, and it occupies the same pocket as ghrelin's acylated N-terminus by mimicking the hydrophobic contacts the octanoyl group makes. GHS-R1a couples to Gq, raising intracellular calcium in the somatotrope, and it has unusually high constitutive activity — it signals without a ligand, at around half of maximum. A receptor already half-on has limited headroom, which is why the difference between two agonists at it is usually potency and pharmacokinetics rather than efficacy. A claim to be dramatically better than MK-677 at this receptor is a claim that runs against its pharmacology.
The specific number to distrust. The figure of "92% greater binding affinity than MK-677" appears on multiple sales pages with no citation anywhere. It is named here so a reader who meets it knows it has been looked for and not found. Binding affinity is reported as a Ki or Kd in nanomolar units against a named radioligand in a named preparation; a bare percentage is not a form in which affinity is ever reported, which is itself informative about where the number came from.
Cell, rodent, human — and where it stops
Step one: there is no step one. For MK-777 specifically there is no cell work, no animal work, no human work, no pharmacokinetics and no toxicology in the public record. The translation chain this section normally walks does not exist for this molecule, and saying so plainly is the most useful thing this page can do.
So here is the chain for the compound it claims to resemble, because that is the only evidence anyone is actually reasoning from, and because the numbers are better than most people who quote them realize.
MK-677 in humans, over two years. Nass 2008 randomized 65 healthy adults aged 60 to 81 to oral MK-677 25 mg daily or placebo, double-blind, for 2 years. Fat-free mass increased by 1.1 kg against a 0.5 kg loss on placebo, P<0.001, and GH and IGF-1 were restored to young-adult levels. That is a genuine, long, well-controlled result and it is the strongest evidence any oral ghrelin mimetic has.
And the same trial reports the cost, in the same paragraph. Appetite increased (and subsided), lower-extremity edema and muscle pain occurred, fasting glucose rose by 0.3 mmol/L and insulin sensitivity fell Nass 2008. A compound that adds a kilogram of fat-free mass over two years and worsens glucose handling is a trade, not a free win.
The class, pooled. Iwai 2022 aside, the broadest estimate comes from Su 2016: 12 studies, 1,377 malnourished patients, ghrelin receptor agonists against placebo. Energy intake rose substantially (standardized mean difference 2.67, 95% CI 1.48–3.85, P<0.001). Body composition changed: lean body mass +0.25 kg, P=0.006; fat mass +0.92 kg, P=0.038; grip strength +0.31 kg, P<0.001.
Read those two body-composition numbers against each other. Fat mass rose nearly four times as much as lean mass. That is the pooled, randomized, human answer for this drug class in the population it works best in — and it is close to the opposite of the recomposition story these compounds are sold on.
The obstacles, and for this compound there is only one that matters. Everything above is about a different molecule. MK-677 is a defined chemical entity with a two-year randomized trial. MK-777 is a name on a capsule. The reasoning "it is like MK-677, so it does what MK-677 does" requires that it is like MK-677, and nobody has published a structure, an assay or an analysis showing that it is anything at all.
MK-777 pharmacokinetics — how much of it actually gets in
The card says the half-life is unknown, and notes that MK-677's ~24 hours belongs to the predecessor. That is exactly right, and here is what can and cannot be inferred from it.
What would degrade it, if it is what it is claimed to be. A non-peptide oral secretagogue is a small molecule, so its clearance would be hepatic: cytochrome P450 oxidation followed by glucuronidation and biliary or renal excretion. That is the route for MK-677, and it is why MK-677 has interaction potential with CYP3A4 inhibitors. None of this has been measured for MK-777 and the inference is only as good as the class assignment, which is unverified.
The oral barrier is the one claim with a testable consequence. The entire practical argument for this compound over the secretagogues that require a subcutaneous injection — ipamorelin, GHRP-2, sermorelin — is oral bioavailability. That is a property of a specific structure — MK-677 achieves it by being a peptidomimetic spiropiperidine rather than a peptide Liu 2021. A capsule with no published structure cannot be assumed to have inherited it, and if the contents are peptidic the oral bioavailability is close to zero and the product does nothing.
The arithmetic that is worth doing anyway. The card lists 10–20 mg daily by analogy to MK-677's 25 mg Nass 2008. If the marketing claim of substantially greater potency were true, then 10–20 mg would be an overdose by the same reasoning that set it — a more potent agonist needs less, not the same. The dose and the potency claim are arithmetically inconsistent with each other, and both come from the same source.
The comparator that settles it. MK-677's ~24-hour half-life supports once-daily dosing and produces sustained receptor occupancy, which is why its trial showed both the IGF-1 rise and the insulin resistance Nass 2008. Whether MK-777 produces hours or a day of exposure changes everything about how it should be used, and there is no measurement.
What would have to be true, and how you would know it was not
Three predictions, and the first is unusual for this Vault: it is a test of whether the product contains anything active at all.
1. IGF-1 is the assay that says whether the capsule is a secretagogue. Any effective GHS-R1a agonist raises GH and therefore IGF-1 — MK-677 restored it to young-adult levels over two years Nass 2008. Draw IGF-1 at baseline and at 8 weeks, same laboratory. A flat IGF-1 after 8 weeks of daily dosing means the capsule is not a working ghrelin receptor agonist, whatever is written on it. This is the cheapest available quality control test for an unregulated product, and for a compound with no literature it is the only one.
2. The prediction that cuts against the product: if it works, glucose handling should get worse. This is not a caveat, it is the class's documented behavior — fasting glucose up 0.3 mmol/L and insulin sensitivity down over two years Nass 2008. Draw fasting insulin and HbA1c at baseline and 12 weeks. Rising IGF-1 with untouched glucose markers would be a genuinely new finding; unchanged IGF-1 with unchanged glucose is the null result and means nothing is happening.
3. The body-composition claim has a specific falsification, and the pooled data predicts it will fail. In 1,377 patients across 12 randomized studies, ghrelin agonists added 0.92 kg of fat against 0.25 kg of lean mass Su 2016. So measure both: a consistent body-composition method at baseline and 12 weeks, not a scale. If a person gains 3 kg and calls it lean mass without measuring, the pooled evidence says roughly four fifths of it was not.
What nobody has tested yet
For this compound the list is short and blunt, because almost everything is unknown. These are the four that could be settled quickly.
Nobody has published what is in the capsule. Liquid chromatography with mass spectrometry on a single capsule would establish whether it contains MK-677, a related secretagogue, or something else entirely. That is a routine analysis at any contract laboratory, it costs less than a month's supply, and it is the single most valuable experiment anyone could do on this product.
Nobody has produced a structure. Without one there is no docking study, no affinity measurement against the now-solved receptor structure Liu 2021, and no way for anyone to check the affinity claim in either direction.
Nobody has measured IGF-1 in a user. Ten people with before-and-after IGF-1 would produce the first pharmacodynamic data this compound has, and would answer the only question that matters — does it do anything — without needing a structure at all.
Nobody has established whether it is a new molecule. The possibility that MK-777 is MK-677 relabeled at a premium, or a mixture, has never been excluded, and it is exactly the possibility the analysis above would settle.
MK-777 — its own safety story, not its class's
The class safety block above assumes a characterized compound. This one is not characterized, and that is the safety story.
The risk is not that MK-777 is dangerous. It is that nobody knows what it is. There is no toxicology, no impurity specification, no dose-finding, and no adverse-event record because there is no record of any kind. Every reassurance available about this product is a reassurance about a different molecule.
If it is a working ghrelin agonist, the class risks apply and they are documented. Increased appetite, lower-extremity edema, muscle pain, raised fasting glucose and reduced insulin sensitivity, all from a two-year randomized trial Nass 2008. And Iwai 2022 reports acute pancreatitis related to a ghrelin receptor agonist — a single case report, which is weak evidence and is the only signal of its kind for this receptor class, so it is named rather than emphasized.
The stacking error is the most likely practical harm. If MK-777 is a GHS-R1a agonist, then running it with MK-677, a GHRP, or a CJC/ipamorelin blend is a double dose at one receptor, not a stack. A receptor with high constitutive activity and a known desensitization pattern responds to that with less signal, not more Liu 2021, so the likely result is a worse outcome at a higher cost and a higher glucose.
The general caution for anything raising IGF-1 applies here too — active or recent malignancy — with the added problem that a person cannot know whether they are raising IGF-1 at all without the blood test above.
The honest bottom line. This is the least-supported compound in this cohort by a wide margin. It is not thin evidence; it is the absence of evidence, wearing the reputation of a molecule that has plenty.
Sources read for this page
- Liu H, et al. Structural basis of human ghrelin receptor signaling by ghrelin and the synthetic agonist ibutamoren. Nature Communications 2021 · PMID 34737341
- Nass R, et al. Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults: a randomized trial. Annals of Internal Medicine 2008 · PMID 18981485
- Iwai N, et al. Gastrointestinal: Acute pancreatitis related to a ghrelin receptor agonist. Journal of Gastroenterology and Hepatology 2022 · PMID 35178754
MK-777 — safety, predicted from mechanism
Predicted from mechanism, not from a human safety trial. How that reasoning works →
What the mechanism predicts
Derived from the molecule, not a trial.
- Read this section knowing the mechanism is an assumption. No published pharmacology confirms that MK-777 binds GHS-R1a. It is sold as a next-generation MK-677 and the ghrelin-receptor mechanism follows from that positioning, not from a measurement. Everything below is what would follow IF it does what it is sold as doing — which is an honest thing to say and a genuinely different thing from a warning derived from established action.
- If it is a ghrelin-receptor agonist, the consequences are the GH-axis consequences: rising fasting glucose and insulin resistance, fluid retention, carpal-tunnel symptoms from that fluid, and joint ache. These are what elevated GH and IGF-1 do where they have been studied.
- Ghrelin agonism also does what ghrelin does, which is appetite. That is the mechanism working rather than a side effect, and it is the reason MK-677 is difficult to run in a deficit. Anyone taking this while cutting should expect the compound to be working against the goal.
- The harm specific to this compound is double-dosing at one receptor. MK-677, Ipamorelin, GHRP-2 and GHRP-6 all act at GHS-R1a. Adding MK-777 to any of them is not a stack — it is the same receptor twice, from two bottles, and nothing on either label will tell you so.
- The GHRP-family peptides raise prolactin and cortisol alongside GH. Whether this one does is not known, which is a reason to measure rather than a reason to assume it does not.
What has actually been reported
- Nothing. No PubMed entry, no trial registry record, no published pharmacology, no adverse-event literature. An empty observed field is the most informative line on this card: it means nobody has looked, which is not the same as nothing having been found.
How to reduce the risk
Same mechanism as the prediction.
- Write out everything you are currently running and check it for anything acting at GHS-R1a before the first dose. This is the one action that addresses the one harm specific to this compound, and it takes two minutes.
- If you are going to run something with no published pharmacology, run it alone. A compound nobody has characterized cannot be disentangled from a stack when something goes wrong — you will not know which bottle to stop.
- Give it a defined window and a defined set of measurements, then stop and look. Open-ended use of an uncharacterized compound accumulates exposure without accumulating information.
What it does to your bloodwork
A fact about the assay.
- Fasting glucose and HbA1c before starting and again at eight to twelve weeks. If the compound works as sold, this is where it shows up first, and it is also the check that matters most.
- IGF-1 at baseline, before the first dose. An IGF-1 drawn on-cycle cannot tell you where you started.
- Prolactin, if you are running it long enough to care about the GHRP-family question nobody has answered for this molecule.
Don't run this if
- Active or suspected malignancy — the IGF-1 logic that governs the rest of this axis applies here too, and applies more cautiously precisely because the pharmacology is unverified.
- You are already running any GHS-R1a agonist. Check before you buy, not after.
- Diagnosed insulin resistance or type 2 diabetes, without a glucose plan and someone to run it past.
The honest unknown
- Whether the compound does anything at all. The '92% greater binding affinity than MK-677' figure repeated across vendor sites has no source anyone can follow — it should be treated as marketing copy, not as a pharmacological finding.
Not medical advice. If you take prescription medication or have a diagnosed condition, check this with a pharmacist or doctor.
MK-777 — interference & stacking
Predicted from mechanism, not from an interaction study. How mechanism-predicted claims are made →
What MK-777 moves on your bloodwork
Expected direction, not a measured one.
- IGF-1 (Insulin-like Growth Factor 1) — ↑ expected to rise
This is the point. IGF-1 rising is the compound doing its job — it is the stable downstream readout of a GH pulse.
What to do: Test it before you start and again at 6–8 weeks. It is the only number that tells you whether the product was real and the dose was enough. - Growth Hormone, Serum — ✕ unreliable here
A random GH level is close to meaningless here. GH is secreted in pulses during deep sleep and sits undetectable between them, so a daytime draw catches a trough almost every time — including when the compound is working perfectly.
What to do: Do not use GH to judge a secretagogue. Read IGF-1 instead. - Fasting Insulin — ↑ expected to rise
GH is a counter-regulatory hormone: it opposes insulin. Fasting insulin and glucose drifting up is the predicted trade-off, not a surprise.
What to do: Check fasting insulin and HbA1c at baseline and again at 8–12 weeks. This is the marker that decides whether you keep running it. - HbA1c (Hemoglobin A1c) — ↑ expected to rise
Same mechanism, longer window — a slow drift rather than a jump.
What to do: Pair it with fasting insulin; either alone can mislead. - Free T4 (Thyroxine) — ↓ expected to fall
GH accelerates the peripheral conversion of T4 to T3, so free T4 can fall while free T3 holds or rises. Read alone it looks like new hypothyroidism, and it usually isn't.
What to do: Run a full thyroid panel rather than TSH alone before concluding anything.
Everything above follows from one fact: these raise GH and therefore IGF-1. Nothing here needs a trial of the specific molecule.
- Dose range and how to work up to it
- When to take it, and why that window
- Cycle length
- Time off between cycles
- Fasted or fed, and when in the day
- Coach Cam's personal notes
- Which compounds push the same lever, and why the dose adds up faster than people count
- What blunts it — the stacks that waste your money
- What compounds the risk, so a side effect arrives sooner than any one of them suggests
- Coach Cam's read on running it alongside the rest of your protocol
Everything above is free and stays free. Skool is where it becomes a plan — MK-777 in an order, with the rest of what you're running.
Unlock in Skool — $10/mo →Bloodwork to run alongside MK-777
Baseline first, then again at 8–12 weeks.
| Marker | What it’s watching for |
|---|---|
| IGF-1 (Insulin-like Growth Factor 1) | The number that actually tracks your GH exposure — dose by this, not by feel |
| Fasting Insulin | GH raises insulin resistance; this moves before glucose does |
| HbA1c (Hemoglobin A1c) | The slower confirmation that the insulin change is real |
| Comprehensive Metabolic Panel (CMP) | Fasting glucose, and liver and kidney at baseline |
The “Running GH Peptides or MK-677” panel covers these in one order — 9 markers, $132.30 with the discount applied.
Check results you already have → · All 103 markers A–Z
MK-777 — frequently asked questions
What is MK-777?
MK-777 (Acetamoren — MK-677 analog GHS) is a gh & growth research compound. Described as a non-peptide agonist at the ghrelin receptor (GHS-R1a) — the same receptor MK-677 acts on, and the same one the injectable ghrelin mimetics (Ipamorelin, GHRP-2/6) hit. Binding there triggers a GH pulse, which raises IGF-1 downstream. Orally bioavailable, which is the practical difference from the peptide secretagogues. Read that mechanism as a CLASS ASSIGNMENT rather than a measured finding: it follows from what the compound is sold as, and no published pharmacology confirms it.
Where can I find MK-777 dosing and protocols?
Dosing, the reconstitution calculator and Coach Cam's full MK-777 protocol are available to members inside Skool. This public page covers what MK-777 is, how it works and the evidence.
What is the half-life of MK-777?
MK-777 has an approximate half-life of Unknown — MK-677's is ~24 hrs, but that is the predecessor, not this, which is part of what determines how often it's dosed.
What's the evidence behind MK-777?
Current evidence level: None independent — no PubMed entry, no trial registry record, no published pharmacology. Every description traces to vendor copy.. MK-777 is offered for research purposes only and is not an approved medicine.
What MK-777 is used for
MK-777 appears under 1 goal in the goal router.
Related GH & Growth compounds
Where this goes next
The pages here are the frameworks. The protocols — the dosing, the order to correct things in, the week-by-week schedule and what to retest — are inside Skool.